Peptide Therapy for Sciatica: Understanding the Benefits

Peptide Therapy for Sciatica and Nerve Pain Combined with Integrative Chiropractic Care

Sciatica can cause sharp, burning, electric, or shooting pain that travels from the lower back into the buttock and leg. Some people also develop numbness, tingling, leg weakness, or difficulty walking.

Sciatica is not a single disease. It is a group of symptoms caused by irritation or pressure affecting a spinal nerve root. Common causes include:

• A lumbar herniated disc
• Spinal stenosis
• Swelling around a nerve root
• Joint or spinal movement problems
• Muscle tension around the pelvis
• An injury from a car accident, fall, or workplace event

Most sciatica treatment plans begin with conservative care. This may include staying active, therapeutic exercise, chiropractic care, physical rehabilitation, medication, and changes in daily movement. Manual therapy may be considered, but guidelines recommend using it as part of a treatment plan that also includes exercise (National Institute for Health and Care Excellence [NICE], 2020).

Peptide research has created interest in another possible layer of care. However, peptides such as ARA-290 and BPC-157 are not established or FDA-approved treatments for sciatica. Most research involving nerve repair is still based on laboratory studies, animal models, or human studies involving other forms of neuropathy.

What Are Peptides?

Peptides are short chains of amino acids. Amino acids are the building blocks the body uses to create proteins. Some peptides act like small messengers that tell cells when to control inflammation, repair damaged tissue, form blood vessels, or support nerve activity.

Researchers are studying several peptides for pain control and tissue healing. Those most often discussed in connection with nerve pain or sciatic nerve research include:

• ARA-290 for neuropathic pain and inflammatory nerve flares
• BPC-157 for experimental tissue and nerve healing
• IKVAV and YIGSR for nerve-supporting biomaterials
• Other investigational peptides for inflammation or soft-tissue recovery

These substances are not all used in the same way. ARA-290 has been studied as a drug candidate. BPC-157 has mainly been studied in animals. IKVAV and YIGSR are usually placed inside experimental scaffolds or hydrogels designed to guide nerve growth.

ARA-290 for Neuropathic Pain

ARA-290, also called cibinetide in some studies, is a small peptide based on part of the erythropoietin molecule. It was created to activate a tissue-protective pathway without causing the red blood cell effects associated with erythropoietin.

ARA-290 may interact with the innate repair receptor. This receptor becomes active during inflammation or tissue injury. Researchers believe this action may help regulate inflammation and reduce abnormal pain signaling.

Small human trials have studied ARA-290 in people with neuropathic pain related to sarcoidosis and diabetes. Some participants reported improvements in neuropathic symptoms. However, these studies did not test ARA-290 as a treatment for lumbar disc herniation or sciatica caused by spinal nerve compression (Dahan et al., 2013; Heij et al., 2012).

ARA-290 should, therefore, be described as an investigational peptide with early human neuropathic-pain research. It should not be presented as a proven treatment for sciatica.

BPC-157 and Tissue-Healing Research

BPC-157 is a synthetic 15-amino-acid peptide based on a protective compound found in gastric tissue. It has attracted attention because animal studies suggest it may affect:

• Blood vessel development
• Nitric oxide pathways
• Inflammatory activity
• Collagen organization
• Tendon and ligament repair
• Muscle healing
• Nerve recovery

In a rat study involving a damaged sciatic nerve, BPC-157 was associated with improved nerve healing and functional recovery. Other animal studies have examined its effects on injured muscles, tendons, ligaments, and blood vessels (Gjurasin et al., 2010; Gwyer et al., 2019).

A 2024 review found that most BPC-157 research involved small animal models. The authors stated that human trials are needed before the peptide can be translated into routine clinical treatment (Cushman et al., 2024).

There is also no strong human evidence showing that BPC-157 can repair a herniated disc. A disc is a complex structure, and repairing it requires more than controlling inflammation. Pressure on a nerve may continue even when surrounding tissue irritation improves.

The FDA has identified limited human safety information and possible concerns involving immune reactions, peptide impurities, and product quality. A July 2026 FDA advisory committee discussion about allowing certain forms of BPC-157 in compounding did not make BPC-157 an FDA-approved drug. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality before being marketed.

IKVAV and YIGSR for Nerve Repair

IKVAV and YIGSR are short sequences taken from laminin. Laminin is an important part of the extracellular matrix, which is the supportive environment around cells.

These sequences are being studied because they may help nerve cells attach, grow, and send new extensions called axons. Researchers have placed IKVAV and YIGSR inside experimental nerve conduits, nanofibers, and hydrogels.

A nerve conduit acts like a small bridge across a damaged nerve. The material provides growing nerve fibers a path to follow. In preclinical studies, IKVAV has supported nerve-cell attachment, neurite growth, and recovery after experimental sciatic nerve injuries. YIGSR has also been studied for Schwann cell attachment and guidance. Schwann cells help protect and repair peripheral nerves (Stocco et al., 2025; Zhang et al., 2021).

This research is exciting, but it does not mean IKVAV or YIGSR can currently be prescribed as routine injections for sciatica. They are mainly components of experimental tissue-engineering systems.

Why Peptides Cannot Remove Mechanical Nerve Pressure

Peptides may influence inflammation or cellular repair. They cannot automatically remove a large disc herniation, widen severe spinal stenosis, or correct every movement problem affecting the lumbar spine.

This is where integrative chiropractic care may play a separate role.

A chiropractor evaluates how the spine, pelvis, hips, muscles, and nerves are working together. Depending on the diagnosis, treatment may include:

• Gentle spinal manipulation or mobilization
• Flexion-distraction techniques
• Soft-tissue treatment
• Nerve-mobility exercises
• Posture correction
• Core and hip strengthening
• Movement retraining
• Gradual return to work or exercise

A randomized trial found that active spinal manipulation provided greater pain relief than simulated manipulation for selected patients with acute back pain, sciatica, and disc protrusion. However, chiropractic treatment is not right for every patient, especially when progressive weakness, severe instability, fracture, infection, or surgical nerve compression is present (Santilli et al., 2006).

The possible value of combined care is based on addressing two different parts of the problem:

• Biological support: Investigational therapies may target inflammation or cellular repair.
• Mechanical care: Chiropractic and rehabilitation may improve movement, reduce irritation, and build support around the affected area.

This is a reasonable clinical model, but research has not yet proven that combining peptides with chiropractic care creates a special synergistic effect for sciatica.

A Multidisciplinary Approach in El Paso

At Injury Medical Clinic PA in El Paso, Texas, Dr. Alexander Jimenez, DC, APRN, FNP-BC, CCST, CFMP, IFMCP, ATN, works with Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine.

Clinic materials identify Dr. Cardenas as the Medical Director and Collaborative Physician, with NPI #1164426749 and Texas MD License #J2933. She brings more than 40 years of internal medicine experience to the multidisciplinary team. Dr. Jimenez directs chiropractic care, neuromusculoskeletal evaluations, functional rehabilitation, and related integrative services.

This type of medical and chiropractic collaboration is common in integrative and injury care settings. The MD provides medical direction and helps assess health risks, medications, chronic diseases, and medical treatment options. The chiropractor evaluates spinal movement, joint mechanics, muscle function, posture, and rehabilitation needs.

The Injury Medical Clinic PA team integrates:

• Chiropractic care
• Medical evaluation and oversight
• Functional medicine
• Personal injury care
• Neurological and orthopedic examinations
• Rehabilitation and corrective exercise
• Nutrition and lifestyle support
• Referrals for imaging or specialist care

For patients injured in car accidents or workplace events, the team may also document symptoms, examination findings, functional limits, treatment progress, and referrals.

Clinical Observations From Dr. Alex Jimenez

Dr. Jimenez’s published clinical observations emphasize that sciatica often involves more than one structure. A patient may have a disc problem along with muscle guarding, limited hip movement, poor posture, weakness, inflammation, and reduced confidence in movement.

His clinical approach examines the whole recovery process rather than focusing only on temporary pain reduction. This may include assessing:

• How symptoms travel down the leg
• Which movements increase or decrease pain
• Muscle strength and reflexes
• Sensation in the legs and feet
• Hip and pelvic movement
• Core stability
• Work and exercise demands
• Sleep, nutrition, and metabolic health

These observations can help guide personalized care, but clinical experience does not replace controlled research. Treatments must still be selected according to the patient’s diagnosis, health history, examination, and current evidence (Jimenez, 2026).

What a Safe Integrative Plan May Look Like

A careful sciatica treatment plan may follow these steps:

1. Confirm the diagnosis. The team determines whether symptoms come from a disc, spinal narrowing, joint dysfunction, muscle entrapment, or another condition.
2. Screen for danger signs. Progressive weakness, loss of bladder or bowel control, saddle numbness, fever, cancer history, or severe trauma requires immediate medical attention.
3. Reduce nerve irritation. The patient may receive position advice, gentle manual care, activity changes, or medical treatment.
4. Restore movement. Chiropractic care and rehabilitation may improve spinal, pelvic, and hip function.
5. Build strength. Progressive exercises help the core, hips, and legs support daily movement.
6. Review experimental options carefully. Any peptide discussion should include its legal status, evidence level, possible risks, product quality, and available alternatives.

Patient Stories Are Not Clinical Proof

Online discussions include people who report less sciatica pain after using BPC-157, TB-500, or ARA-290. These stories may be meaningful to the individuals sharing them, but they cannot show whether the peptide caused the change.

People may also be using exercise, medication, physical therapy, injections, or lifestyle changes at the same time. Online products may have uncertain ingredients, strength, purity, or sterility. A personal report should therefore be viewed as a reason for further research, not proof of safety or effectiveness.

The Bottom Line

ARA-290, BPC-157, IKVAV, and YIGSR are being investigated for pain control, tissue healing, or nerve regeneration. ARA-290 has limited human research involving certain neuropathic conditions. BPC-157 research is mainly based on animal studies. IKVAV and YIGSR are largely being studied inside experimental nerve scaffolds.

None is an established treatment for sciatica.

Integrative chiropractic care may help selected patients by addressing spinal movement, muscle tension, mechanical irritation, strength, and rehabilitation. Medical oversight adds important screening, medication review, diagnostic guidance, and safety monitoring.

At Injury Medical Clinic PA, Dr. Jimenez and Dr. Cardenas represent a multidisciplinary model that brings chiropractic care, internal medicine oversight, functional medicine, personal injury services, and rehabilitation together. The safest approach is to treat the confirmed cause of sciatica while being honest about what peptide research has—and has not—proven.

---

References

Core Medical & Wellness. (2026). Peptide therapy for pain management: A regenerative medicine guide.

Cushman, C. J., et al. (2024). Local and systemic peptide therapies for soft tissue regeneration: A narrative review. Yale Journal of Biology and Medicine, 97(3), 399–413.

Dahan, A., et al. (2013). ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.

Frisco Spinal Rehabilitation. (2026). Can BPC-157 heal a herniated disc? What patients with back pain should know.

Gjurasin, M., et al. (2010). Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury.

Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.

Heij, L., et al. (2012). Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy.

Ina Chicago. (n.d.). What are the benefits of nerve pain peptides?.

Jimenez, A. (2026). Integrative peptide therapy with chiropractic care explained.

Jimenez, A. (n.d.). Dr. Alex Jimenez: Chiropractic, functional medicine, and injury care.

National Institute for Health and Care Excellence. (2020). Low back pain and sciatica in people over 16: Assessment and management.

Reddit. (2026). Some anecdote and personal data from a recent experience with peptides.

Santilli, V., Beghi, E., & Finucci, S. (2006). Chiropractic manipulation in the treatment of acute back pain and sciatica with disc protrusion. The Spine Journal, 6(2), 131–137.

Stocco, E., et al. (2025). Self-assembling peptides for sciatic nerve regeneration: A review of conduit microenvironment modeling strategies in preclinical studies. Frontiers in Cell and Developmental Biology, 13, 1637189.

U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks.

Zhang, M., Li, L., An, H., Zhang, P., & Liu, P. (2021). Repair of peripheral nerve injury using hydrogels based on self-assembled peptides. Gels, 7(4), 152.